Multidisciplinary team approach for CKD-associated osteoporosis
- PMID: 39315700
- PMCID: PMC11852330
- DOI: 10.1093/ndt/gfae197
Multidisciplinary team approach for CKD-associated osteoporosis
Abstract
Chronic kidney disease-mineral and bone disorder (CKD-MBD) contributes substantially to the burden of cardiovascular disease and fractures in patients with CKD. An increasing arsenal of diagnostic tools, including bone turnover markers and bone imaging, is available to support clinicians in the management of CKD-associated osteoporosis. Although not mandatory, a bone biopsy remains useful in the diagnostic workup of complex cases. In this special report, the European Renal Osteodystrophy (EUROD) initiative introduces the concept of a kidney-bone multidisciplinary team (MDT) for the diagnosis and clinical management of challenging cases of CKD-associated osteoporosis. In 2021, the EUROD initiative launched virtual clinical-pathological case conferences to discuss challenging cases of patients with CKD-associated osteoporosis, in whom a bone biopsy was useful in the diagnostic workup. Out of these, we selected four representative cases and asked a kidney-bone MDT consisting of a nephrologist, an endocrinologist and a rheumatologist to provide comments on the diagnostic and therapeutic choices. These cases covered a broad spectrum of CKD-associated osteoporosis, including bone fracture in CKD G5D, post-transplant bone disease, disturbed bone mineralization, severely suppressed bone turnover and severe hyperparathyroidism. Comments from the MDT were, in most cases, complementary to each other and additive to the presented approach in the cases. The MDT approach may thus set the stage for improved diagnostics and tailored therapies in the field of CKD-associated osteoporosis. We demonstrate the clinical utility of a kidney-bone MDT for the management of patients with CKD-MBD and recommend their establishment at local, national, and international levels.
Keywords: bone biopsy; chronic kidney disease–mineral and bone disorder; multidisciplinary team; osteoporosis; renal osteodystrophy.
© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.
Conflict of interest statement
D.H. reports research grant from Vifor Pharma and Gedeon Richter and consultancy fees and lecture fees from UCB Nordic, GSK and AstraZeneca. A.C.F. reports lecture fees from Vifor and AstraZeneca. R.J. received fees as site PI in a pharmacy-initiated study (SHP634-401) of Takeda. S.K. reports consultancy fees from Vifor Pharma, GSK and Bayer, and lecture fees from AstraZeneca. M.H.L.-P. reports research grant from Kiowa Kirin. K.E.S.P. educational fora lecture fees and honoraria from UCB and Amgen, with all fees donated to charity via waiver before undertaking the work. P.E. reports research grant from Vifor Pharma, and consultancy fees and lecture fees from UCB and Vifor Pharma. M.H. advisory board Resverlogix and employee at Diaverum AB. H.S.J., T.L.A., A.F., H.K., L.M., and X.T. report no conflicts of interest.
Figures






References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical